Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

Ildiko LingvayKirstine Brown-FrandsenHelen M ColhounJohn DeanfieldScott S EmersonSille EsbjergSøren Hardt-LindbergG Kees HovinghSteven E KahnRobert F KushnerA Michael LincoffSteven P MarsoTea Monk FriesJorge PlutzkyDonna H Ryannull null

Published in: Obesity (Silver Spring, Md.) (2022)

The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.

Keyphrases

weight loss
type diabetes
metabolic syndrome
weight gain
adipose tissue
social media
health information
high fat diet induced